异基因造血细胞移植后接受抗CD19嵌合抗原受体T细胞治疗后的移植物抗宿主病:移植并发症与儿科疾病工作组联合EBMT研究
该EBMT注册研究纳入2018至2022年间257例因B-ALL或B-NHL在异基因造血干细胞移植后接受抗CD19 CAR-T治疗的患者的资料,分析移植后抗CD19 CAR-T治疗后移植物抗宿主病(GvHD)的发生率。新发急性GvHD的100天累积发生率为1.6%,新发慢性GvHD的12个月累积发生率为2.8%。研究认为该场景下GvHD发生率相对较低,GvHD不是主要安全性问题。
要点
- 257例allo-HCT后接受抗CD19 CAR-T治疗的患者中,3例发生aGvHD,6例发生cGvHD。
- 新发aGvHD的100天累积发生率为1.6%,新发cGvHD的12个月累积发生率为2.8%。
- 1年GvHD无复发生存率为52.1%,1年非复发死亡率为4.7%,中位随访18.8个月时1年总生存率为76.8%。
核心结论
- 在allo-HCT后接受抗CD19 CAR-T治疗的患者中,GvHD发生率相对较低,数据支持GvHD不是该场景下的主要安全性问题。
研究设计与样本
- EBMT注册研究,纳入257例allo-HCT后接受抗CD19 CAR-T治疗的B-ALL或B-NHL患者,其中172例≥18岁。
- 患者接受tisagenlecleucel(n=184)、brexucabtagene autoleucel(n=43)或axicabtagene ciloleucel(n=30),治疗时间为2018年至2022年。
主要发现
- 3例患者发生aGvHD,6例患者发生cGvHD。
- 新发aGvHD的100天累积发生率为1.6%,新发cGvHD的12个月累积发生率为2.8%。
- 1年GvHD无复发生存率为52.1%,1年非复发死亡率为4.7%。
- 中位随访18.8个月,1年总生存率为76.8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients diagnosed with B-acute lymphoblastic leukemia (B-ALL) or B-non-Hodgkin's lymphoma (B-NHL) relapsing after allogeneic stem cell transplantation (allo-HCT), it is a standard practice to perform anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. When collected from the patient after allo-HCT, the produced CAR-T cells are likely to be donor T-cell-derived, creating unknown safety risks due to their potential allo-reactivity. We therefore performed an EBMT registry-based study on the incidence of graft-versus-host disease (GvHD) in this setting. We included 257 allo-HCT patients (n = 172 ≥ 18 years) with B-ALL or B-NHL, treated with anti-CD19 CAR T-cells (tisagenlecleucel n = 184, brexucabtagene autoleucel n = 43 and axicabtagene ciloleucel n = 30), between 2018 and 2022. Three patients developed aGvHD, whereas 6 patients developed cGvHD after CAR T-cell. The 100-day cumulative incidence (CI) of new aGvHD was 1.6% and the 12-month CI of new cGvHD was 2.8%. The 1-year GvHD relapse-free survival and non-relapse mortality were 52.1% and 4.7%, respectively. Last, with a median follow up of 18.8 months, the 1-year overall survival was 76.8%. In summary, the GvHD rate in allo-HCT patients treated with CAR T-cell therapy is relatively low. Our data support the view that GvHD is not a major safety issue in this setting.
引用
- Ortí G, Peczynski C, Boreland W, et al. Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study. Leukemia. 2024. PMID: 39562721. doi:10.1038/s41375-024-02467-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。